Experiment Protocol Biomedical Engineer in Israel Tel Aviv –Free Word Template Download with AI

This Experiment Protocol outlines the methodology for a clinical engineering study conducted in Tel Aviv, Israel. The primary objective is to validate the efficacy and safety of a newly developed subcutaneous biosensor designed for continuous glucose monitoring (CGM). As a Biomedical Engineer, the lead researcher is tasked with bridging the gap between theoretical device design and practical clinical application. Tel Aviv serves as an ideal location for this study due to its status as a global hub for medical technology innovation and its advanced healthcare infrastructure.

The study aims to address specific challenges in diabetes management by improving sensor accuracy and reducing calibration frequency. This protocol adheres strictly to the ethical guidelines set forth by the Israeli Ministry of Health and the institutional review boards of Tel Aviv University.

The specific objectives of this Experiment Protocol are as follows:

1. To assess the analytical accuracy of the prototype biosensor against standard venous blood glucose measurements.
2. To evaluate the biocompatibility and skin irritation potential of the sensor insertion site over a 14-day period.
3. To analyze the signal stability of the device under the environmental conditions typical of Tel Aviv, including high humidity and temperature variations.
4. To ensure the device complies with international electromagnetic compatibility (EMC) standards relevant to hospital environments in Israel.

3.1 Study Design

This is a prospective, single-arm, open-label study. The Biomedical Engineer will oversee the technical implementation, data acquisition, and device troubleshooting. The study will be conducted at a designated research clinic in central Tel Aviv.

3.2 Participant Selection

Participants will be recruited from the local population in Tel Aviv and surrounding areas. Inclusion criteria include:

• Adults aged 18 to 65 years.
• Diagnosed with Type 1 or Type 2 diabetes.
• Resident of Israel with access to follow-up care in Tel Aviv.
• Ability to provide informed consent in Hebrew or English.

Exclusion criteria include known allergies to sensor materials, history of severe skin reactions, or concurrent participation in other interventional studies.

3.3 Device Preparation and Calibration

As the lead Biomedical Engineer, the investigator will perform rigorous pre-clinical testing on each sensor unit. This includes:

• Verification of sensor impedance and baseline current.
• Calibration using standard glucose solutions.
• Packaging under sterile conditions compliant with ISO 13485 standards.

Upon arrival at the Tel Aviv clinic, devices will be stored at controlled temperatures to maintain integrity prior to application.

3.4 Data Collection Procedures

Data collection will occur over a 14-day period. Participants will wear the prototype biosensor on the upper arm. Reference blood glucose measurements will be taken using a standard glucometer at fasting, post-prandial, and bedtime intervals. The Biomedical Engineer will remotely monitor the data stream transmitted by the sensors to detect anomalies or signal loss in real-time.

Safety is paramount in this Experiment Protocol. Potential risks include minor skin irritation, infection at the insertion site, and inaccurate glucose readings leading to inappropriate insulin dosing.

Mitigation strategies include:

• Providing participants with a backup standard glucometer.
• Establishing a 24/7 hotline managed by the research team in Tel Aviv for immediate medical consultation.
• Regular site inspections by the Biomedical Engineer to assess skin integrity.

Any adverse events will be documented and reported to the Institutional Review Board (IRB) in accordance with Israeli regulations.

The Biomedical Engineer will utilize statistical software to analyze the collected data. Key metrics include:

• Mean Absolute Relative Difference (MARD) between sensor readings and reference values.
• Clark Error Grid analysis to assess clinical accuracy.
• Correlation coefficients to determine the strength of the relationship between the biosensor and venous blood glucose.

Data will be anonymized to protect participant privacy, adhering to the Israeli Privacy Protection Law.

This study has been reviewed and approved by the Ethics Committee of Tel Aviv University. All participants will provide written informed consent before enrollment. The protocol respects the autonomy, dignity, and rights of all subjects. The Biomedical Engineer is committed to maintaining the highest standards of integrity and transparency throughout the research process.

This Experiment Protocol provides a comprehensive framework for evaluating the novel biosensor in a real-world clinical setting in Tel Aviv, Israel. By leveraging the expertise of a Biomedical Engineer and the advanced medical infrastructure of the region, this study aims to contribute significantly to the field of diabetes management technology. Successful completion of this protocol will pave the way for regulatory approval and commercialization of the device.